Key regions: Germany, South Korea, France, United States, United Kingdom
Anti-coagulants are a class of drugs that prevent blood clotting and are used to treat and prevent blood clots. The market for anti-coagulants in the D-A-CH region (Germany, Austria, and Switzerland) has been experiencing steady growth in recent years.
Customer preferences: Patients in the D-A-CH region have shown a preference for oral anti-coagulants over injectable ones. This is due to the convenience and ease of use of oral medications. Additionally, patients in this region tend to be more cautious about taking medications and prefer drugs with a proven safety record.
Trends in the market: One of the major trends in the anti-coagulants market in the D-A-CH region is the increasing use of direct oral anti-coagulants (DOACs) over traditional anti-coagulants such as warfarin. DOACs are more convenient to use and have fewer side effects than traditional anti-coagulants. Additionally, there has been a trend towards personalized medicine, where patients are given individualized treatment plans based on their genetic makeup and other factors.
Local special circumstances: Germany is the largest market for anti-coagulants in the D-A-CH region, accounting for the majority of sales. The German healthcare system is highly regulated, which has led to lower prices for drugs. In Austria and Switzerland, anti-coagulants are more expensive due to the lack of price controls.
Underlying macroeconomic factors: The aging population in the D-A-CH region has led to an increase in the incidence of conditions that require anti-coagulant therapy, such as atrial fibrillation and deep vein thrombosis. Additionally, the increasing prevalence of obesity and sedentary lifestyles has contributed to the rise in blood clot-related conditions. The overall economic stability and high GDP per capita in the D-A-CH region have also contributed to the growth of the anti-coagulants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
